New Amsterdam Pharma
David Topper has worked in the financial sector since 1983, when they began their career at Morgan Stanley as Managing Director, Head of Equity Capital Markets, Head of Industrials and HY Corp Finance Groups. In 2005, they moved to J.P. Morgan, where they served as Head of Equity Capital Markets, Chairman Equity Commitments Committee, and Vice Chairman Investment Bank. From 2012 to 2020, they were a Partner at General Atlantic and an Investor and Board Observer at CircleUp. During this time, they also served as a Board Member at Amherst Pierpont Securities LLC. In 2020, they joined Frazier Lifesciences Acquisition Corp. as CFO and Board Director, and Frazier Healthcare Partners as Partner, Capital Markets. Most recently, in 2023, they became Chief Financial Officer at NewAmsterdam Pharma.
David Topper obtained a BA in Economics and Political Science from Duke University between 1975 and 1979. David then went on to earn an MBA in Business from Stanford University between 1981 and 1983.
This person is not in any offices
New Amsterdam Pharma
1 followers
Founded in 2019 by the venture capital firm Forbion and John Kastelein, NewAmsterdam Pharma is a privately held, clinical-stage company focused on the research and development of transformative therapies for cardiometabolic diseases. Its mission is to improve patient care in populations where traditional therapies are not tolerated or have been unsuccessful.